CDKL5: A Potential Drug Target and Biomarker for Cancer (G6792)

Target Name: CDKL5

NCBI ID: G6792

CDKL5

CDKL5: A Potential Drug Target and Biomarker for Cancer

Introduction

CDKL5 (Serine/Threonine-Protein Kinase 9) is a protein that plays a crucial role in cell signaling pathways, particularly in the regulation of cell growth, differentiation, and survival. CDKL5 is a member of the T-CAF (Tumor suppressor gene- controlled angiogenesis factor) family, which includes several other proteins involved in cancer progression. Activated CDKL5 has been implicated in the development and progression of various types of cancer, including breast, ovarian, and colorectal cancers. As a result, targeting CDKL5 has become an attractive research focus for cancer scientists.

CDKL5 Expression and Localization

CDKL5 is a 21-kDa protein that is expressed in a variety of tissues, including skeletal muscles, heart, brain, and various cancers. Its localization is primarily in the cytoplasm, where it is involved in the regulation of cytoskeletal assembly and stability (1 ). CDKL5 has been shown to play a role in the regulation of cell adhesion, migration, and invasion, as well as in the establishment of cell-to-cell contact and the formation of blood vessels.

CDKL5 as a Potential Drug Target

The potential of CDKL5 as a drug target is based on several factors. First, its well-established role in cell signaling pathways, including the regulation of cell growth, differentiation, and survival. Second, its involvement in the regulation of cytoskeletal assembly and stability , which can potentially impact the stability and flexibility of cells, making them more susceptible to external stimuli. Third, its role in cell-to-cell contact and the formation of blood vessels, which can contribute to the development of invasive and metastatic phenotypes ( 3).

CDKL5 has been shown to play a role in the regulation of various cellular processes, including cell adhesion, migration, and invasion. For example, studies have shown that CDKL5 can physically interact with the adhesion molecule E-cadherin and influence the distribution of cadherins in breast epithelial cells. Additionally, CDKL5 has been shown to play a role in the regulation of cell migration, as it has been shown to promote the migration of cancer cells in a xenoblastoma virus (XV) reporter cell line.

CDKL5 has also been shown to contribute to the regulation of cell survival. For example, studies have shown that CDKL5 can promote the survival of cancer cells by inhibiting cell apoptosis and promoting cell cycle progression.

CDKL5 as a Biomarker

The potential use of CDKL5 as a biomarker for cancer has also been explored. The regulation of CDKL5 expression and activity has been shown to be associated with various cellular processes, including cell adhesion, migration, and survival. As a result, CDKL5 has been suggested as a potential biomarker for cancer, particularly for those tumors that are resistant to traditional cancer therapies.

CDKL5 has been shown to have potential as a biomarker for various types of cancer, including breast, ovarian, and colorectal cancers. For example, studies have shown that CDKL5 is overexpressed in various types of cancer, including breast cancer, and that its expression is associated with poor prognosis. Additionally, studies have shown that CDKL5 is involved in the regulation of cell cycle progression and apoptosis, which can potentially impact the sensitivity of cancer cells to traditional cancer therapies.

Conclusion

In conclusion, CDKL5 is a protein that has been implicated in the development and progression of various types of cancer. Its well-established role in cell signaling pathways, including the regulation of cell growth, differentiation, and survival, as well as its involvement in the regulation of

Protein Name: Cyclin Dependent Kinase Like 5

Functions: Mediates phosphorylation of MECP2 (PubMed:15917271, PubMed:16935860). May regulate ciliogenesis (PubMed:29420175)

The "CDKL5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CDKL5 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets